Alzheimer’s disease (AD) is often associated with the buildup of amyloid plaques and tau tangles in the brain, but new research suggests that an entirely different factor may play a crucial role in determining who develops symptoms and how quickly the disease progresses. A study published in Nature Communications introduces the concept of individual bioenergetic capacity—a person’s ability to maintain energy balance—as a potential source of resilience against Alzheimer’s disease.

Metabolism and Alzheimer’s: A Missing Link?

One of the earliest signs of Alzheimer’s is glucose hypometabolism, where the brain struggles to use glucose for energy. However, some individuals with the same neuropathological markers of Alzheimer’s show delayed or less severe cognitive decline, suggesting that factors beyond amyloid and tau accumulation may contribute to disease progression. This study proposes that bioenergetic capacity, or the ability to efficiently generate energy through alternative pathways such as fat and protein metabolism, could explain this variability.

Using fasting blood acylcarnitine profiles, researchers identified distinct metabolic subgroups among study participants. Acylcarnitines serve as markers of mitochondrial function and fatty acid oxidation, offering a window into an individual’s overall energy metabolism. The findings were striking:

• Individuals with stronger beta-oxidation efficiency (the process of breaking down fats for energy) showed better cognitive performance and lower Alzheimer’s biomarkers, such as reduced tau and amyloid accumulation.
• Higher bioenergetic resilience was associated with slower brain aging and disease progression, even among individuals at high risk for Alzheimer’s.
• Bioenergetic capacity appears to be both genetically influenced and modifiable, meaning that lifestyle factors could play a role in preserving cognitive function.

Potential for New Alzheimer’s Therapies

One of the most compelling aspects of this research is that targeting energy metabolism could be as effective as existing anti-amyloid treatments. The study suggests that improving bioenergetic capacity—either through lifestyle interventions or pharmaceutical approaches—could help delay cognitive decline in at-risk individuals.

Possible strategies to enhance bioenergetic health include:

• Nutritional interventions such as low-carb or ketogenic diets, which promote fat metabolism and may help compensate for impaired glucose utilization in the brain.
• Exercise regimens designed to boost mitochondrial efficiency and energy production.
• Metabolic drugs like metformin, which has shown potential in improving mitochondrial function and reducing neurodegenerative risk factors.

A Paradigm Shift in Alzheimer’s Research

The study also introduces a new biomarker for Alzheimer’s risk: bioenergetic age, a measure of how efficiently an individual’s metabolism functions relative to their chronological age. Researchers found that bioenergetic age was strongly correlated with Alzheimer’s biomarkers, cognitive function, and future disease progression. This suggests that a simple blood test measuring acylcarnitine levels could one day help predict Alzheimer’s risk years before symptoms appear—offering a window for early intervention.

These findings challenge the conventional view of Alzheimer’s as solely a neurodegenerative condition and instead position it as a metabolic disease influenced by systemic energy balance. If bioenergetic resilience proves to be a key determinant of Alzheimer’s progression, future treatments may shift from targeting amyloid plaques to optimizing metabolic health as a means of delaying or preventing cognitive decline.

This study represents a significant step toward a new era of Alzheimer’s prevention and treatment, where maintaining energy balance in the body and brain could become a primary focus in preserving cognitive health.

Sources: 

https://www.nature.com/articles/s41467-025-57032-0
Arnold, M., Buyukozkan, M., Doraiswamy, P. M., Nho, K., Wu, T., Gudnason, V., Launer, L. J., Wang-Sattler, R., Adamski, J., The Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Metabolomics Consortium, De Jager, P. L., Ertekin-Taner, N., Bennett, D. A., Saykin, A. J., Peters, A., Suhre, K., Kaddurah-Daouk, R., Kastenmüller, G., & Krumsiek, J. (2025). Individual bioenergetic capacity as a potential source of resilience to Alzheimer’s disease. Nature Communications, 16(1910).